Related Jobs
-
Technical Manager, Regulatory Affairs Development
Job Type: Permanent
Salary: Salary on application
Location: Belgium -
Director Regulatory Affairs
Job Type: Permanent
Salary: Excellent salary
Location: Switzerland
J&JPRD: ADHD drug gets US approval for adults
30 Jun 2008
Regulatory Affairs
The drug Concerta has been granted approval for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in US adults, Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) says.
It is approved for use in adults aged 18 to 65, in daily doses which range from 18 to 72 milligrams.
Commenting on the drug, J&JPRD says an initial dose of medication is delivered when the tablet is ingested, with medication then delivered into the bloodstream at a controlled rate throughout the day.
Janet Vergis, president of McNeil Pediatrics, a division of Ortho-McNeil-Janssen Pharmaceuticals, says there is a growing body of knowledge on adult ADHD which suggests "a challenging burden of impairment in everyday functioning".
She continues: "We see today's approval as a treatment option milestone for adults with ADHD and their healthcare professionals."
Earlier this month, the Johnson & Johnson Nordic AB division of the company announced its acquisition of Amic.
The Swedish firm is a developer of in vitro diagnostic technologies that can be used outside the physical confines of the laboratory.
